Nucleus Genomics Considers $0.40 per Share Offer to Acquire 23andMe

Nucleus Genomics has announced its consideration of a public offer to acquire 23andMe, contingent on securing financing and successful negotiations. The proposal aims to revitalize consumer health care. However, the rest of 23andMe's board previously turned down a similar proposal in late July due to the offered price per share of $0.40 and lack of committed funding. 23andMe has struggled financially, never making a profit, as its business model relies on one-time genetics tests and unsuccessful attempts to develop a subscriber base and DNA database for pharmaceuticals.